| 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party M Heuser, SD Freeman, GJ Ossenkoppele, F Buccisano, CS Hourigan, ... Blood, The Journal of the American Society of Hematology 138 (26), 2753-2767, 2021 | 478 | 2021 |
| Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancer ECM Kooijmans, A Bökenkamp, NS Tjahjadi, JM Tettero, ... Cochrane Database of Systematic Reviews, 2019 | 120 | 2019 |
| Technical aspects of flow cytometry-based measurable residual disease quantification in acute myeloid leukemia: experience of the European LeukemiaNet MRD Working Party JM Tettero, S Freeman, V Buecklein, A Venditti, L Maurillo, W Kern, ... Hemasphere 6 (1), e676, 2022 | 57 | 2022 |
| 2021 update measurable residual disease in acute myeloid leukemia: European leukemia net working party consensus document M Heuser, SD Freeman, GJ Ossenkoppele, F Buccisano, CS Hourigan, ... Blood 138 (26), 2753-2767, 2021 | 38 | 2021 |
| Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively … JM Tettero, LL Ngai, C Bachas, DA Breems, T Fischer, BT Gjertsen, ... Haematologica 108 (10), 2794, 2023 | 13 | 2023 |
| Extreme hypercalcaemia caused by immobilisation due to acute spinal cord injury JM Tettero, E van Eeghen, AJ Kooter BMJ Case Reports 14 (6), 2021 | 12 | 2021 |
| Machine learning allows the identification of new Co-mutational patterns with prognostic implications in NPM1 mutated AML-results of the European harmony alliance A Hernandez Sanchez, A Villaverde Ramiro, E Straeng, C Gastone, ... Blood 140 (Supplement 1), 739-742, 2022 | 11 | 2022 |
| Prospective validation of the prognostic relevance of CD34+CD38– AML stem cell frequency in the HOVON-SAKK132 trial LL Ngai, D Hanekamp, F Janssen, J Carbaat-Ham, MAMA Hofland, ... Blood, The Journal of the American Society of Hematology 141 (21), 2657-2661, 2023 | 9 | 2023 |
| AML/normal progenitor balance instead of total tumor load (MRD) accounts for prognostic impact of flowcytometric residual disease in AML D Hanekamp, JM Tettero, GJ Ossenkoppele, A Kelder, J Cloos, ... Cancers 13 (11), 2597, 2021 | 7 | 2021 |
| Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications – a HARMONY study A Hernández-Sánchez, T González, M Sobas, E Sträng, G Castellani, ... Leukemia 38 (9), 1929-1937, 2024 | 6 | 2024 |
| Analytical assay validation for acute myeloid leukemia measurable residual disease assessment by multiparametric flow cytometry JM Tettero, N Dakappagari, ME Heidinga, Y Oussoren‐Brockhoff, ... Cytometry Part B: Clinical Cytometry 104 (6), 426-439, 2023 | 6 | 2023 |
| Machine Learning Allows the Identification of New Co-Mutational Patterns with Prognostic Implications in NPM1 Mutated AML-Results of the European Harmony Alliance AH Sánchez, AV Ramiro, E Sträng, C Gastone, CA Heckman, J Versluis, ... Blood 140, 739-742, 2022 | 6 | 2022 |
| Erratum: Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working … JM Tettero, SD Freeman, V Buecklein, A Venditti, L Maurillo, W Kern, ... HemaSphere 6 (3), E703, 2022 | 6 | 2022 |
| Impact of hemodilution on flow cytometry based measurable residual disease assessment in acute myeloid leukemia JM Tettero, ME Heidinga, TR Mocking, G Fransen, A Kelder, WJ Scholten, ... Leukemia 38 (3), 630-639, 2024 | 5 | 2024 |
| Rearrangements Involving 11q23/KMT2A: Mutational Landscape and Prognostic Implications-Results of the Harmony Alliance AML Database A Hernandez Sanchez, T González, MA Sobas, E Sträng, C Gastone, ... Blood 140 (Supplement 1), 551-554, 2022 | 4 | 2022 |
| Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome-and cost-analysis JM Tettero, WKW Al-Badri, LL Ngai, C Bachas, DA Breems, ... Frontiers in oncology 12, 999822, 2022 | 3 | 2022 |
| S130: NPM1 mutated AML: impact of co-mutational patterns-results of the European Harmony Alliance A Hernández-Sánchez, Á Villaverde-Ramiro, JM Elicegui, T Gonzalez, ... HemaSphere 6, 31-32, 2022 | 3 | 2022 |
| Covering Hierarchical Dirichlet Mixture Models on binary data to enhance genomic stratifications in onco-hematology D Dall’Olio, E Sträng, AT Turki, JM Tettero, M Barbus, R Schulze-Rath, ... PLoS computational biology 20 (2), e1011299, 2024 | 1 | 2024 |
| The Laip-Based-Dfn Approach Is Superior in Terms of Useful MRD Results As Compared to the Laip Approach after Cycle II in Acute Myeloid Leukemia LL Ngai, D Hanekamp, A Kelder, W Scholten, J Carbaat-Ham, ... Blood 142, 1572, 2023 | 1 | 2023 |
| Prognostic Value of Measurable Residual Disease in High-Risk Myelodysplastic Syndromes with Intensive Chemotherapy Treatment: Analysis of HOVON-SAKK Studies LL Ngai, CR Veenstra, P Gradowska, A Kelder, W Scholten, AN Snel, ... Blood 142 (Supplement 1), 323-323, 2023 | 1 | 2023 |
